JP2024501257A5 - - Google Patents

Info

Publication number
JP2024501257A5
JP2024501257A5 JP2023538074A JP2023538074A JP2024501257A5 JP 2024501257 A5 JP2024501257 A5 JP 2024501257A5 JP 2023538074 A JP2023538074 A JP 2023538074A JP 2023538074 A JP2023538074 A JP 2023538074A JP 2024501257 A5 JP2024501257 A5 JP 2024501257A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
co2h
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023538074A
Other languages
English (en)
Japanese (ja)
Other versions
JP7851934B2 (ja
JP2024501257A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/064881 external-priority patent/WO2022140555A1/en
Publication of JP2024501257A publication Critical patent/JP2024501257A/ja
Publication of JP2024501257A5 publication Critical patent/JP2024501257A5/ja
Application granted granted Critical
Publication of JP7851934B2 publication Critical patent/JP7851934B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023538074A 2020-12-23 2021-12-22 神経変性疾患の治療のための、インダニルを含むカルボン酸化合物 Active JP7851934B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063130023P 2020-12-23 2020-12-23
US63/130,023 2020-12-23
PCT/US2021/064881 WO2022140555A1 (en) 2020-12-23 2021-12-22 Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases

Publications (3)

Publication Number Publication Date
JP2024501257A JP2024501257A (ja) 2024-01-11
JP2024501257A5 true JP2024501257A5 (cg-RX-API-DMAC7.html) 2024-12-23
JP7851934B2 JP7851934B2 (ja) 2026-04-27

Family

ID=82160119

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023538074A Active JP7851934B2 (ja) 2020-12-23 2021-12-22 神経変性疾患の治療のための、インダニルを含むカルボン酸化合物

Country Status (7)

Country Link
US (1) US12624003B2 (cg-RX-API-DMAC7.html)
EP (1) EP4267117B1 (cg-RX-API-DMAC7.html)
JP (1) JP7851934B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230124992A (cg-RX-API-DMAC7.html)
CN (1) CN116685313A (cg-RX-API-DMAC7.html)
ES (1) ES3073110T3 (cg-RX-API-DMAC7.html)
WO (1) WO2022140555A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240021883A (ko) 2021-06-16 2024-02-19 셀진 코포레이션 신경변성 질환의 치료를 위한 카르복실산 기를 포함하는 아제티디닐 화합물
WO2023107563A1 (en) * 2021-12-07 2023-06-15 Celgene Corporation Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases
CN120019042A (zh) * 2022-07-18 2025-05-16 细胞基因公司 用于治疗神经退行性疾病的化合物
US20260209203A1 (en) * 2022-12-16 2026-07-23 Celgene Corporation Heterocyclic Compounds as Modulators of S1P5

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE496024T1 (de) * 2002-12-20 2011-02-15 Merck Sharp & Dohme 1-(amino)indane als edg-rezeptoragonisten
US7632854B2 (en) 2004-11-17 2009-12-15 Pfizer Italia S.R.L. Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US8217027B2 (en) * 2006-12-21 2012-07-10 Abbott Laboratories Sphingosine-1-phosphate receptor agonist and antagonist compounds
US8637528B2 (en) * 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
US8592426B2 (en) 2011-01-24 2013-11-26 Hoffmann—La Roche Inc. Aryl-benzocycloalkyl amide derivatives
BR112016022575A2 (pt) 2014-03-28 2017-08-15 Azevan Pharmaceuticals Inc Composições e métodos para o tratamento de doenças neurodegenerativas
EP3228615B1 (en) 2014-12-04 2021-01-20 ONO Pharmaceutical Co., Ltd. Dihydronaphthalene derivatives useful in the treatment of s1p5-mediated diseases
US10280159B2 (en) 2015-12-22 2019-05-07 AbbVie Deutschland GmbH & Co. KG Fused (hetero)cyclic compounds as S1P modulators

Similar Documents

Publication Publication Date Title
JP2024050527A5 (cg-RX-API-DMAC7.html)
JP2023540344A5 (cg-RX-API-DMAC7.html)
JP2021534124A5 (cg-RX-API-DMAC7.html)
JP2021514001A5 (cg-RX-API-DMAC7.html)
JP2011509309A5 (cg-RX-API-DMAC7.html)
JP2020515610A5 (cg-RX-API-DMAC7.html)
JP2022185107A5 (cg-RX-API-DMAC7.html)
JP2022534426A5 (cg-RX-API-DMAC7.html)
JP2022512482A5 (cg-RX-API-DMAC7.html)
JP2023531311A5 (cg-RX-API-DMAC7.html)
JP2021516232A5 (cg-RX-API-DMAC7.html)
JP2024522718A5 (cg-RX-API-DMAC7.html)
JP2010529051A5 (cg-RX-API-DMAC7.html)
JP2012503018A5 (cg-RX-API-DMAC7.html)
JP2010532768A5 (cg-RX-API-DMAC7.html)
JP2022510925A5 (cg-RX-API-DMAC7.html)
JP2013542267A5 (cg-RX-API-DMAC7.html)
JP2011530545A5 (cg-RX-API-DMAC7.html)
JP2020533352A5 (cg-RX-API-DMAC7.html)
JP2019513745A5 (cg-RX-API-DMAC7.html)
JP2020111571A5 (cg-RX-API-DMAC7.html)
AR121299A1 (es) Inhibidores heterocíclicos de pad4
JP2005539045A5 (cg-RX-API-DMAC7.html)
RU2008107733A (ru) Ингибиторы gsk-3
RU2010113358A (ru) Гуанидинсодержащие соединения, применимые в качестве антагонистов мускариновых рецепторов